Advertisement
UK markets close in 6 hours 9 minutes
  • FTSE 100

    8,089.05
    +48.67 (+0.61%)
     
  • FTSE 250

    19,726.78
    +7.41 (+0.04%)
     
  • AIM

    755.02
    +0.33 (+0.04%)
     
  • GBP/EUR

    1.1672
    +0.0027 (+0.23%)
     
  • GBP/USD

    1.2518
    +0.0056 (+0.45%)
     
  • Bitcoin GBP

    51,146.74
    -1,923.54 (-3.62%)
     
  • CMC Crypto 200

    1,362.72
    -19.85 (-1.44%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    82.88
    +0.07 (+0.08%)
     
  • GOLD FUTURES

    2,339.20
    +0.80 (+0.03%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,990.40
    -98.30 (-0.54%)
     
  • CAC 40

    8,056.81
    -35.05 (-0.43%)
     

Merck’s Inorganic Growth Strategy in 2019

Merck’s Inorganic Growth Strategy in 2019

On April 2, Merck & Co. issued a press release announcing the successful completion of its cash tender offer for Immune Design, with 86.75% of the target’s total outstanding common stock tendered on a fully diluted basis.